Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept. 1. Moroney co-founded the antibody company in 1992.

Kress served as president and CEO of rare autoimmune disease company Syntimmune Inc., which was acquired by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) at the end of last year, and has held executive positions at Biogen Inc. (NASDAQ:BIIB) and Sanofi Genzyme. MorphoSys said Moroney will step down on Sept. 1 and will continue to support Kress during a transition period...